Opinion|Videos|January 5, 2024
Adverse Events Seen With JAK Inhibitors for Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Why Is Lung Health Key to Survivorship After Cancer Treatment?
2
New Combination Treatment Approach Studied in Pancreatic Cancer
3
U.S. Soccer Legend Kasey Keller Reveals Lymphoma Journey
4
The Power of Personalized Care in Breast Cancer Treatment
5